Cord Blood Stem Cells get new Lease of Life and Quality臍血幹細胞獲得新的契約生活和質量
Biotech firm Chemokine Therapeutics discovered that chemokine analog CTCE-0214 has the ability to enhance survival and expansion of human cord blood stem cells.生物科技公司趨化因子療法，發現趨化因子模擬ctce - 0214有能力，以提高生存和擴展人類臍帶血幹細胞。 Studies show CTCE-0214 can multiply the number of stem cells and related progenitor cell subsets from human cord blood through a process called ex-vivo expansion.研究顯示， ctce - 0214可以乘以數量的幹細胞和祖細胞的相關子從人臍血通過一個過程，所謂的前體外擴增。
The CTCE-0214 treated stem cells demonstrated significantly improved survival as well as markedly enhanced engraftment characteristics in an experimental model of stem cell transplantation.該ctce - 0214治療幹細胞表現出顯著改善生存以及顯著增強的特點，在植入實驗模型的造血幹細胞移植。
The capacity of cord blood to treat cancer and a wide range of degenerative diseases is directly related to the quantity and quality of stem cells in cord blood.的能力，臍血治療癌症和廣泛的退行性疾病，是直接關係到數量和質量的幹細胞的臍血。 CTCE-0214 in a dose-dependent manner significantly increased the expansion of all cell subsets studied, including important cell subtypes called CFU-GEMM and SCID-repopulating cells, which have been identified as important stem cells for clinical use. ctce - 0214在劑量依賴性地顯著增加的擴大，所有細胞亞群的研究，包括重要的細胞亞型所謂的CFU - gemm和SCID - repopulating細胞，已被確定為重要的幹細胞移植的臨床應用。
Improved methods to increase the number of the most primitive stem cells are expected to expand the potential therapeutic uses of cord blood in regenerative medicine.改進的方法數目增加最原始的幹細胞，預計擴大潛在的治療用途的臍血在再生醫學。
Source: Datamonitor Newswire資料來源：公司Datamonitor社
